ATP7A Inhibitors
ATP7A Inhibitors represent a diverse array of chemical compounds strategically designed to impede the functional activity of the copper-transporting P-type ATPase ATP7A. This class includes both direct inhibitors, which competitively interfere with copper binding, and indirect inhibitors that modulate crucial pathways influencing ATP7A-mediated copper homeostasis. Direct inhibitors, such as CuCl2, BCA, and Neocuproine, exert their inhibitory effects by directly interacting with copper ions, thereby hindering ATP7A's ability to acquire copper for transport. These compounds highlight the competitive nature of copper binding within the cellular milieu, offering precise tools to modulate ATP7A function in conditions where copper levels need meticulous control.
Indirect inhibitors, such asTetrathiomolybdate and Triethylenetetramine, function by modulating cellular copper homeostasis. For instance, Atox1, a copper chaperone, can indirectly inhibit ATP7A by sequestering copper and disrupting its transfer to ATP7A. Similarly, Tetrathiomolybdate, a copper chelator, limits substrate availability for ATP7A by reducing intracellular copper levels. These indirect inhibitors showcase the importance of understanding the intricate interplay between copper-regulating molecules and ATP7A to effectively modulate copper transport processes. Furthermore, compounds like Pyrrolidine dithiocarbamate and MG132 exert indirect inhibition by influencing NF-κB signaling and proteasomal degradation, respectively. By altering these pathways, these compounds indirectly impact ATP7A-mediated copper homeostasis, emphasizing the regulatory roles of cellular context in copper transport processes. In conclusion, the chemical class of ATP7A Inhibitors encompasses a variety of compounds with diverse mechanisms of action, ranging from direct competition for copper binding to indirect modulation of crucial cellular pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin indirectly inhibits ATP7A by interfering with copper-dependent processes. As a platinum-containing compound, Cisplatin disrupts copper homeostasis and compromises ATP7A function by influencing cuproenzyme biogenesis. | ||||||
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
NH4Cl indirectly inhibits ATP7A by altering lysosomal pH. By increasing lysosomal acidity, NH4Cl disrupts copper trafficking and influences ATP7A function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, indirectly inhibits ATP7A by disrupting copper-dependent proteasomal degradation. By impairing proteasomal function, Bortezomib hampers the turnover of proteins involved in copper homeostasis, leading to altered ATP7A-mediated copper transport. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin indirectly inhibits ATP7A by impacting copper-dependent chaperone function. As a heat shock protein 90 (Hsp90) inhibitor, Geldanamycin disrupts Hsp90-mediated copper delivery to ATP7A. | ||||||
Copper(II) chloride | 7447-39-4 | sc-252631 sc-252631A | 50 g 250 g | $51.00 $82.00 | ||
CuCl2 directly inhibits ATP7A by competitively interfering with copper binding. As a copper salt, CuCl2 competes with ATP7A for available copper ions, leading to reduced copper incorporation into ATP7A and compromised copper transport. | ||||||
Bicinchoninic acid disodium salt | 979-88-4 | sc-278767 sc-278767A sc-278767C sc-278767B | 1 g 50 g 250 g 500 g | $104.00 $270.00 $999.00 $3027.00 | 3 | |
BCA directly inhibits ATP7A by sequestering copper ions. As a copper chelator, BCA forms stable complexes with copper, preventing ATP7A from accessing copper for transport. | ||||||
Neocuproine | 484-11-7 | sc-257893 sc-257893A sc-257893B sc-257893C sc-257893D | 1 g 5 g 25 g 100 g 250 g | $34.00 $90.00 $297.00 $1108.00 $2388.00 | 1 | |
Neocuproine acts as a direct inhibitor of ATP7A by forming copper complexes. By chelating copper ions, Neocuproine interferes with ATP7A-mediated copper transport, leading to compromised copper homeostasis. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $33.00 $64.00 | 11 | |
Pyrrolidine dithiocarbamate indirectly inhibits ATP7A by modulating NF-κB signaling. As an inhibitor of IκB kinase, Pyrrolidine dithiocarbamate disrupts the NF-κB pathway, leading to altered expression of genes involved in copper homeostasis. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132, a proteasome inhibitor, indirectly inhibits ATP7A by influencing copper-dependent proteasomal degradation. By impairing proteasomal function, MG132 disrupts the turnover of proteins involved in copper homeostasis, leading to altered ATP7A-mediated copper transport. | ||||||